FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985935801> ?p ?o ?g. }

• W1985935801 endingPage "21" @default.
• W1985935801 startingPage "11" @default.
• W1985935801 abstract "Objective: Information on psychostimulant treatment in long-term studies for attention-deficit/hyperactivity disorder (ADHD) in adolescents is limited. This study aimed to assess the safety and effectiveness of lisdexamfetamine dimesylate (LDX) over 52 weeks in adolescents with ADHD. Methods: This open-label multicenter study enrolled eligible participants after their participation in a randomized, double-blind, placebo-controlled 4 week trial in adolescents with ADHD. Following a 4 week dose-optimization phase, participants were maintained on treatment for up to ∼48 weeks on an optimal dose. Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, laboratory findings, and electrocardiograms. Effectiveness measures included the ADHD Rating Scale IV (ADHD-RS-IV; primary) and Clinical Global Impressions-Improvement (CGI-I). The Youth Quality of Life-Research Version (YQOL-R) was also included in this study; raw scores are transformed to a 0–100 point scale. Results: Of 269 enrolled (from the antecedent study), 265 (98.5%) were in the safety population and effectiveness population. Common TEAEs (≥5%) with LDX included upper respiratory tract infection (21.9%), decreased appetite (21.1%), headache (20.8%), decreased weight (16.2%), irritability (12.5%), insomnia (12.1%), nasopharyngitis (7.2%), influenza (6.8%), dizziness (5.3%), and dry mouth (5.3%). At end point, for all LDX doses in the overall safety population, mean (SD) increase from baseline in systolic blood pressure was 2.3 (10.53) mm Hg, diastolic blood pressure was 2.5 (8.37) mm Hg, and pulse rate was 6.3 (12.74) bpm. No clinically meaningful electrocardiogram or vital sign changes were observed. At end point with LDX treatment, the ADHD-RS-IV mean (SD) total score change from antecedent study baseline was −26.2 (9.75) (p<0.001); 87.2% of participants were improved (CGI-I=1 or 2). Baseline (antecedent study) mean (SD) YQOL-R perceptual total score was 79.8 (11.28) and increased by 3.9 (9.73) at end point (p<0.001). Conclusions: LDX demonstrated a long-term safety profile similar to that of other long-acting psychostimulants and was effective, as indicated by improvements in ADHD symptoms and participant-perceived YQOL, in adolescents with ADHD. Clinical Trial Registration: NCT00764868, http://www.clinicaltrials.gov/ct2/show/NCT00764868?term=SPD489-306&rank=1" @default.
• W1985935801 created "2016-06-24" @default.
• W1985935801 creator A5003133423 @default.
• W1985935801 creator A5010997382 @default.
• W1985935801 creator A5024208230 @default.
• W1985935801 creator A5038305189 @default.
• W1985935801 creator A5042787535 @default.
• W1985935801 creator A5075001232 @default.
• W1985935801 creator A5082771218 @default.
• W1985935801 date "2013-02-01" @default.
• W1985935801 modified "2023-09-28" @default.
• W1985935801 title "A Long-Term Open-Label Safety and Effectiveness Trial of Lisdexamfetamine Dimesylate in Adolescents With Attention-Deficit/Hyperactivity Disorder" @default.
• W1985935801 cites W1853960255 @default.
• W1985935801 cites W1966782848 @default.
• W1985935801 cites W1968113055 @default.
• W1985935801 cites W1979206088 @default.
• W1985935801 cites W1993782358 @default.
• W1985935801 cites W1994391757 @default.
• W1985935801 cites W2018548383 @default.
• W1985935801 cites W2029569572 @default.
• W1985935801 cites W2047200439 @default.
• W1985935801 cites W2052372131 @default.
• W1985935801 cites W2058463020 @default.
• W1985935801 cites W2059069438 @default.
• W1985935801 cites W2062714266 @default.
• W1985935801 cites W2077454035 @default.
• W1985935801 cites W2090962270 @default.
• W1985935801 cites W2092107327 @default.
• W1985935801 cites W2114290463 @default.
• W1985935801 cites W2131679908 @default.
• W1985935801 cites W2134734723 @default.
• W1985935801 cites W2156971947 @default.
• W1985935801 cites W2163659555 @default.
• W1985935801 cites W2171074660 @default.
• W1985935801 cites W2285134444 @default.
• W1985935801 cites W2490103761 @default.
• W1985935801 cites W266727927 @default.
• W1985935801 cites W2744661960 @default.
• W1985935801 cites W2885275597 @default.
• W1985935801 cites W4243902683 @default.
• W1985935801 cites W4318598290 @default.
• W1985935801 cites W76668800 @default.
• W1985935801 doi "https://doi.org/10.1089/cap.2011.0088" @default.
• W1985935801 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23410138" @default.
• W1985935801 hasPublicationYear "2013" @default.
• W1985935801 type Work @default.
• W1985935801 sameAs 1985935801 @default.
• W1985935801 citedByCount "25" @default.
• W1985935801 countsByYear W19859358012013 @default.
• W1985935801 countsByYear W19859358012014 @default.
• W1985935801 countsByYear W19859358012015 @default.
• W1985935801 countsByYear W19859358012016 @default.
• W1985935801 countsByYear W19859358012017 @default.
• W1985935801 countsByYear W19859358012018 @default.
• W1985935801 countsByYear W19859358012019 @default.
• W1985935801 countsByYear W19859358012020 @default.
• W1985935801 crossrefType "journal-article" @default.
• W1985935801 hasAuthorship W1985935801A5003133423 @default.
• W1985935801 hasAuthorship W1985935801A5010997382 @default.
• W1985935801 hasAuthorship W1985935801A5024208230 @default.
• W1985935801 hasAuthorship W1985935801A5038305189 @default.
• W1985935801 hasAuthorship W1985935801A5042787535 @default.
• W1985935801 hasAuthorship W1985935801A5075001232 @default.
• W1985935801 hasAuthorship W1985935801A5082771218 @default.
• W1985935801 hasConcept C118552586 @default.
• W1985935801 hasConcept C126322002 @default.
• W1985935801 hasConcept C142724271 @default.
• W1985935801 hasConcept C15744967 @default.
• W1985935801 hasConcept C168563851 @default.
• W1985935801 hasConcept C1862650 @default.
• W1985935801 hasConcept C187212893 @default.
• W1985935801 hasConcept C197934379 @default.
• W1985935801 hasConcept C204787440 @default.
• W1985935801 hasConcept C27081682 @default.
• W1985935801 hasConcept C2779034229 @default.
• W1985935801 hasConcept C2780783007 @default.
• W1985935801 hasConcept C2780820931 @default.
• W1985935801 hasConcept C2908647359 @default.
• W1985935801 hasConcept C558461103 @default.
• W1985935801 hasConcept C71924100 @default.
• W1985935801 hasConcept C84393581 @default.
• W1985935801 hasConcept C99454951 @default.
• W1985935801 hasConceptScore W1985935801C118552586 @default.
• W1985935801 hasConceptScore W1985935801C126322002 @default.
• W1985935801 hasConceptScore W1985935801C142724271 @default.
• W1985935801 hasConceptScore W1985935801C15744967 @default.
• W1985935801 hasConceptScore W1985935801C168563851 @default.
• W1985935801 hasConceptScore W1985935801C1862650 @default.
• W1985935801 hasConceptScore W1985935801C187212893 @default.
• W1985935801 hasConceptScore W1985935801C197934379 @default.
• W1985935801 hasConceptScore W1985935801C204787440 @default.
• W1985935801 hasConceptScore W1985935801C27081682 @default.
• W1985935801 hasConceptScore W1985935801C2779034229 @default.
• W1985935801 hasConceptScore W1985935801C2780783007 @default.
• W1985935801 hasConceptScore W1985935801C2780820931 @default.
• W1985935801 hasConceptScore W1985935801C2908647359 @default.
• W1985935801 hasConceptScore W1985935801C558461103 @default.
• W1985935801 hasConceptScore W1985935801C71924100 @default.

• next